Zadeh Aryan Rafiee, Eghbal Aynaz Foroughi, Mirghazanfari Seyed Mahdi, Ghasemzadeh Mohammad Reza, Nassireslami Ehsan, Donyavi Vahid
AJA University of Medical Sciences, Tehran, Iran.
School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
J Res Med Sci. 2022 Apr 15;27:28. doi: 10.4103/jrms.jrms_823_21. eCollection 2022.
Here, we aimed to investigate the therapeutic effects of extract on serum brain-derived neurotrophic factor (BDNF) and depression score in patients with depression.
This clinical trial was performed in 2021 in the hospitals of military forces in Tehran on 52 male patients with major depressive disorder treated with sertraline. We used the Depression, Anxiety, and Stress Scale-21 Items (DASS-21) questionnaire to assess the patients. Serum BDNF levels were measured by the enzyme-linked immunosorbent assay. Patients were then divided into two groups receiving 1000 mg oil extract, daily, and placebo. Both groups received sertraline for at least 3 months. DASS-21 questionnaire and serum BDNF levels were measured after 10 weeks.
After treatments, we observed significantly decreased DASS-21 score (-11.24 ± 5.69) in the intervention group ( < 0.001) and placebo (-2.72 ± 6.19, = 0.032), but patients in the intervention group had significantly lower scores (50.1 ± 6.8 vs. 58.2 ± 5.6, respectively, < 0.001). Furthermore, patients in the intervention group had significantly decreased depression score (-5.5 ± 2.47, < 0.001) and lower scores compared to the placebo ( < 0.001) (18.6 ± 2.7 vs. 23.4 ± 2.1 in intervention and placebo, respectively). We also observed significantly increased BDNF levels in the intervention group after the treatments (6.08 ± 3.76, < 0.001) compared to the placebo group (29.4 ± 3.6 vs. 24.9 ± 2.1, < 0.001). Serum BDNF levels had also significant reverse correlations with DASS-21 score ( = -0.35, = 0.011) and depression score ( = -0.45, = 0.001).
The use of resulted in decreased depression score and increase in serum BDNF levels that indicate the importance and efficacy of this drug.
在此，我们旨在研究[提取物名称]对抑郁症患者血清脑源性神经营养因子（BDNF）及抑郁评分的治疗效果。
这项临床试验于2021年在德黑兰的军队医院对52名接受舍曲林治疗的男性重度抑郁症患者进行。我们使用抑郁、焦虑和压力量表-21项（DASS-21）问卷对患者进行评估。采用酶联免疫吸附测定法测量血清BDNF水平。然后将患者分为两组，一组每天接受1000毫克[提取物名称]油提取物，另一组接受安慰剂。两组均接受舍曲林治疗至少3个月。10周后测量DASS-21问卷和血清BDNF水平。
治疗后，我们观察到干预组的DASS-21评分显著降低（-11.24±5.69）（P<0.001），安慰剂组也降低（-2.72±6.19，P = 0.032），但干预组患者的评分显著更低（分别为50.1±6.8和58.2±5.6，P<0.001）。此外，干预组患者的抑郁评分显著降低（-5.5±2.47，P<0.001），与安慰剂组相比评分更低（P<0.001）（干预组和安慰剂组分别为18.6±2.7和23.4±2.1）。我们还观察到治疗后干预组的BDNF水平与安慰剂组相比显著升高（6.08±3.76，P<0.001）（分别为29.4±3.6和24.9±2.1，P<0.001）。血清BDNF水平与DASS-21评分（r = -0.35，P = 0.011）和抑郁评分（r = -0.45，P = 0.001）也存在显著的负相关。
使用[提取物名称]导致抑郁评分降低和血清BDNF水平升高，这表明该药物的重要性和疗效。
